<scp>MRI</scp> Distance Measures as a Predictor of Subsequent Clinical Status During the Preclinical Phase of Alzheimer's Disease and Related Disorders

Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has been shown to predict subsequent cognitive impairment among individuals who were cognitively normal when first evaluated, indicating that subtle brain atrophy associated with Alzheimer's disease (AD) may begin years before clinical symptoms appear. Traditionally, atrophy has been quantified by differences in brain volume or thickness over a specified timeframe. Research indicates that the rate of atrophy varies across different brain regions, which themselves exhibit complex spatial and hierarchical organizations. These characteristics collectively emphasize the need for diverse summary measures that can effectively capture the multidimensional nature of degeneration. In this study, we explore the use of distance measurements to quantify brain volumetric changes using processed MRI data from the Preclinical Alzheimer's Disease Consortium (PAC). We conducted a series of analyses to predict future diagnostic status by modeling MRI trajectories for participants who were cognitively normal at baseline and either remained cognitively normal or progressed to mild cognitive impairment (MCI) over time, with adjustments for age, sex, education, and APOE genotype. We consider multiple distance measures and brain regions through a two-step approach. First, we build base models by fitting individual mixed-effect models for each distance metric and brain region pairing, using follow-up diagnosis (normal vs. MCI) as the outcome and volumetric changes from the baseline, as summarized by a given distance measure, as predictors. The second step aggregates these individual region-distance base models to derive an overall estimate of diagnostic status. Our analyses showed that the distance measures approach consistently outperformed the traditional direct volumetric approach in terms of predictive accuracy, both in individual base models and the aggregated models. This work highlights the potential advantage of using distance measures over the traditional direct volumetric approach to capture the multidimensional aspects of atrophy in the development of AD and related disorders.

Authors

Institutions

Publication Details

Journal
Human Brain Mapping
Published
2025-04-15
DOI
https://doi.org/10.1002/hbm.70205
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MRI Distance Measures as a Predictor of Subsequent Clinical Status During the Preclinical Phase of Alzheimer's Disease and Related Disorders

Tammie L.S. Benzinger, Susan M. Resnick, Anja Soldan, Jürgen Fripp et al.
1 links
Human Brain Mapping
Dementia and Cognitive Impairment Research
article

MRI Distance Measures as a Predictor of Subsequent Clinical Status During the Preclinical Phase of Alzheimer's Disease and Related Disorders

Tammie L.S. Benzinger, Susan M. Resnick, Anja Soldan, Jürgen Fripp, Christos A. Davatzikos, Corinne Pettigrew, Guray Erus, Brian Caffo, Colin L. Masters, Walter A. Kukull, Sterling C. Johnson, Murat Bilgel, Xinyi Zhang, Zheyu Wang, John C. Morris, Marilyn S. Albert
article en

Abstract

Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has been shown to predict subsequent cognitive impairment among individuals who were cognitively normal when first evaluated, indicating that subtle brain atrophy associated with Alzheimer's disease (AD) may begin years before clinical symptoms appear. Traditionally, atrophy has been quantified by differences in brain volume or thickness over a specified timeframe. Research indicates that the rate of atrophy varies across different brain regions, which themselves exhibit complex spatial and hierarchical organizations. These characteristics collectively emphasize the need for diverse summary measures that can effectively capture the multidimensional nature of degeneration. In this study, we explore the use of distance measurements to quantify brain volumetric changes using processed MRI data from the Preclinical Alzheimer's Disease Consortium (PAC). We conducted a series of analyses to predict future diagnostic status by modeling MRI trajectories for participants who were cognitively normal at baseline and either remained cognitively normal or progressed to mild cognitive impairment (MCI) over time, with adjustments for age, sex, education, and APOE genotype. We consider multiple distance measures and brain regions through a two-step approach. First, we build base models by fitting individual mixed-effect models for each distance metric and brain region pairing, using follow-up diagnosis (normal vs. MCI) as the outcome and volumetric changes from the baseline, as summarized by a given distance measure, as predictors. The second step aggregates these individual region-distance base models to derive an overall estimate of diagnostic status. Our analyses showed that the distance measures approach consistently outperformed the traditional direct volumetric approach in terms of predictive accuracy, both in individual base models and the aggregated models. This work highlights the potential advantage of using distance measures over the traditional direct volumetric approach to capture the multidimensional aspects of atrophy in the development of AD and related disorders.

Human Brain MappingVol. 46(6)
University of Wisconsin–Madison (US), Johns Hopkins University (US), The University of Melbourne (AU), University of Washington (US), Washington University in St. Louis (US), Florey Institute of Neuroscience and Mental Health (AU), National Institute on Aging (US), Australian e-Health Research Centre (AU), CSIRO Health and Biosecurity (AU), Sidney Kimmel Comprehensive Cancer Center (US), University of Pennsylvania (US)
Commonwealth Scientific and Industrial Research Organisation, National Institutes of Health, National Institute on Aging, National Institute on Drug Abuse, National Institute of Biomedical Imaging and Bioengineering
Quality Education
Openalex Percentile: Top 89%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.